| Literature DB >> 32407259 |
Kang Cheng1, Chen-Fu Liu2, Guo-Wu Rao1.
Abstract
Tumor growth inhibition can be achieved by inhibiting angiogenesis, which has been a field of great concern in recent years. Important targets to inhibit angiogenesis include vascular endothelial growth factor receptor (VEGFR) and its homologous tyrosine kinase receptor. Anti-angiogenic therapy based on inhibition of VEGFR-2 is an effective clinical treatment strategy. The research progress of VEGFR-2 inhibitors is reviewed in this paper from the aspects of drug development and chemical synthesis. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.Entities:
Keywords: Tumor; VEGFR-2 inhibitor; anti-angiogenic agents; approved drugs; synthesis.; tyrosine kinase
Mesh：
Substances：
Year: 2021 PMID： 32407259 DOI： 10.2174/0929867327666200514082425
Source DB: PubMed Journal: Curr Med Chem ISSN： 0929-8673 Impact factor: 4.530